Basic Information
| LncRNA/CircRNA Name | LINC00565 |
| Synonyms | NA |
| Region | GRCh38_13:113926514-113928844 |
| Ensemble | ENSG00000260910 |
| Refseq | NR_047495 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | 2 | ||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | ovarian cancer |
| ICD-0-3 | C56.9 |
| Methods | qRT-PCR, Western blot analysis |
| Sample | tissue samples,OC cell lines (OVCAR3, SKOV3, HO8910, A2780 and HEY) and human-derived normal ovarian cell line (IOSE) |
| Expression Pattern | up-regulated |
| Function Description | LINC00565, a novel lncRNA, was highly expressed in ovarian cancer (OC). LINC00565 expression level was negatively associated with outcomes of OC patients. Further analysis showed that LINC00565 expression was closely correlated to tumor size, FIGO stage.knockdown of LINC00565 significantly inhibited proliferative, invasive and migratory abilities of ovarian cancer cells. Besides, knockdown of LINC00565 can induce cell cycle arrest in G0/G1 phase.LINC00565 knockdown markedly downregulated the protein expressions of CyclinD1, CyclinE1 and CDK4, but upregulated the expression of P16 and P21. |
| Pubmed ID | 31819497 |
| Year | 2019 |
| Title | Upregulated LINC00565 Accelerates Ovarian Cancer Progression By Targeting GAS6 |
External Links
| Links for LINC00565 | GenBank HGNC NONCODE |
| Links for ovarian cancer | OMIM COSMIC |